Gemcabene calcium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525160

CAS#: 209789-08-2 (calcium)

Description: Gemcabene is a lipid-lowering small molecule to be used as an adjunctive therapy to reduce LDL-C, hsCRP, and TGs. Gemcabene is a first-in-class oral drug candidate with pleiotropic properties similar to statins as shown in trials to date. Gemcabene has a unique mechanism of action that involves the: (1) blocking the production of hepatic triglyceride and cholesterol synthesis; and (2) enhancing the clearance of VLDL by decreasing ApoC-III.


Price and Availability

Size
Price

Size
Price

Size
Price

Gemcabene calcium is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 525160
Name: Gemcabene calcium
CAS#: 209789-08-2 (calcium)
Chemical Formula: C16H28CaO5
Exact Mass: 302.20932
Molecular Weight: 340.47
Elemental Analysis: C, 56.44; H, 8.29; Ca, 11.77; O, 23.50


Related CAS #: 209789-08-2 (calcium)   183293-82-5 (free base)    

Synonym: Gemcabene; Gemcabene [INN]; PD 72953; PD-72953.

IUPAC/Chemical Name: calcium 6,6'-oxybis(2,2-dimethylhexanoate)

InChi Key: ZJKZKKPIKDNHDM-UHFFFAOYSA-L

InChi Code: InChI=1S/C16H30O5.Ca/c1-15(2,13(17)18)9-5-7-11-21-12-8-6-10-16(3,4)14(19)20;/h5-12H2,1-4H3,(H,17,18)(H,19,20);/q;+2/p-2

SMILES Code: O=C([O-])C(C)(C)CCCCOCCCCC(C)(C)C([O-])=O.[Ca+2]


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Goodman MD, McPartland S, Huber K, Saif MW. New developments in the management of borderline resectable pancreatic cancers. JOP. 2013 Jul 10;14(4):334-6. doi: 10.6092/1590-8577/1681. PubMed PMID: 23846921.

2: Gagnon J, Anini Y. Glucagon stimulates ghrelin secretion through the activation of MAPK and EPAC and potentiates the effect of norepinephrine. Endocrinology. 2013 Feb;154(2):666-74. doi: 10.1210/en.2012-1994. Epub 2013 Jan 10. PubMed PMID: 23307791.

3: Yuan H, Feng B, Yu Y, Chupka J, Zheng JY, Heath TG, Bond BR. Renal organic anion transporter-mediated drug-drug interaction between gemcabene and quinapril. J Pharmacol Exp Ther. 2009 Jul;330(1):191-7. doi: 10.1124/jpet.108.149476. Epub 2009 Apr 6. PubMed PMID: 19349522.

4: Peterkin VC, Bauman JN, Goosen TC, Menning L, Man MZ, Paulauskis JD, Williams JA, Myrand SP. Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes. Br J Clin Pharmacol. 2007 Oct;64(4):458-68. Epub 2007 Jun 6. PubMed PMID: 17555467; PubMed Central PMCID: PMC2048551.

5: Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, Corrigan BW, Lockwood PA, Marshall SA, Benincosa LJ, Tensfeldt TG, Parivar K, Amantea M, Glue P, Koide H, Miller R. Model-based drug development. Clin Pharmacol Ther. 2007 Jul;82(1):21-32. Epub 2007 May 23. Review. PubMed PMID: 17522597.

6: Mandema JW, Hermann D, Wang W, Sheiner T, Milad M, Bakker-Arkema R, Hartman D. Model-based development of gemcabene, a new lipid-altering agent. AAPS J. 2005 Oct 7;7(3):E513-22. Review. PubMed PMID: 16353929; PubMed Central PMCID: PMC2751254.

7: Bauman JN, Goosen TC, Tugnait M, Peterkin V, Hurst SI, Menning LC, Milad M, Court MH, Williams JA. Udp-glucuronosyltransferase 2b7 is the major enzyme responsible for gemcabene glucuronidation in human liver microsomes. Drug Metab Dispos. 2005 Sep;33(9):1349-54. Epub 2005 Jun 24. PubMed PMID: 15980101.

8: Bays H, Stein EA. Pharmacotherapy for dyslipidaemia--current therapies and future agents. Expert Opin Pharmacother. 2003 Nov;4(11):1901-38. Review. PubMed PMID: 14596646.

9: Bays HE, McKenney JM, Dujovne CA, Schrott HG, Zema MJ, Nyberg J, MacDougall DE; Gemcabene Study Group. Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol. Am J Cardiol. 2003 Sep 1;92(5):538-43. PubMed PMID: 12943873.

10: Suckling K. Pharmacological modification of lipoprotein(a). Biochem Soc Trans. 1999 Aug;27(4):466-9. Review. PubMed PMID: 10917622.

11: Huang NH, Kagel JR, Rossi DT. Automated solid-phase extraction workstations combined with quantitative bioanalytical LC/MS. J Pharm Biomed Anal. 1999 Mar;19(3-4):613-20. PubMed PMID: 10704127.

12: Bisgaier CL, Essenburg AD, Barnett BC, Auerbach BJ, Haubenwallner S, Leff T, White AD, Creger P, Pape ME, Rea TJ, Newton RS. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. J Lipid Res. 1998 Jan;39(1):17-30. Erratum in: J Lipid Res 1998 Jun;39(6):1317. PubMed PMID: 9469582.